REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
| Title: | Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor |
| Presenter: | John Knox, Ph.D. |
| Abstract Number: | ND03 |
| Session: | New Drugs on the Horizon: Part 1 |
| Date/Time: | 1:45 – 2:00 p.m. PT on April 7, 2024 |
| Title: | RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor |
| Presenter: | Elena Koltun, Ph.D., Wei Lin, M.D. |
| Session: | KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology |
| Date/Time: | 1:00 – 1:20 p.m. PT on April 9, 2024 |
| Title: | Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC |
| Presenter: | Xing Wei, Ph.D. |
| Abstract Number: | 6585 |
| Session: | Novel Antitumor Agents 5 |
| Date/Time: | 2:35 – 2:50 p.m. PT on April 9, 2024 |
Revolution Medicines Poster Presentations:
| Title: | Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models |
| Presenter: | Lillian Seu, Ph.D. |
| Abstract Number: | 581/4 |
| Session: | Immunotherapy |
| Date/Time: | 1:30 – 5:00 p.m. PT on April 7, 2024 |
| Title: | RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors |
| Presenter: | Zhe Chen, M.B.B.S., Ph.D. |
| Abstract Number: | 3340/28 |
| Session: | Novel Antitumor Agents 3 |
| Date/Time: | 1:30 – 5:00 p.m. PT on April 8, 2024 |
| Title: | The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers |
| Presenter: | Priyanka Bapat, Ph.D. |
| Abstract Number: | 4709/2 |
| Session: | Other Cellular Mechanisms for Anticancer Drug Action |
| Date/Time: | 9:00 a.m. – 12:30 p.m. PT on April 9, 2024 |
Collaborator Poster Presentations:
| Title: | RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models |
| Lead RevMed Co-Author: | Harshit Shah, Ph.D. |
| Abstract Number: | 1924/2 |
| Session: | Drug Resistance 2: RAS GTPase |
| Date/Time: | 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 |
| Title: | Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors |
| Lead RevMed Co-Author: | Jingjing Jiang, Ph.D. |
| Abstract Number: | 1927/5 |
| Session: | Drug Resistance 2: RAS GTPase |
| Date/Time: | 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 |
Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).
| Last Trade: | US$57.02 |
| Daily Change: | -0.05 -0.09 |
| Daily Volume: | 106,997 |
| Market Cap: | US$9.520B |
November 06, 2024 October 25, 2024 October 23, 2024 October 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
